Genomic alterations – a Brave New World for cancer treatment?
New meeting on genomics in cancer treatment
The advent of genome sequencing is bringing about a quiet revolution in healthcare. Yet while the thirst for advanced genomic knowledge may seem enticing, doctors know that information without interpretation may not be very useful.
We are pleased to announce a new high-level scientific meeting that explores ways to better use existing research data in order to improve clinical oncologists’ personalised treatment programs for cancer patients.
The 3rd edition of the Molecular Analysis for Personalised therapy meeting (MAP) will be held 13-14 October in Zurich, diving into the most pressing issues in this field.
• What are the actionable genomic alterations in frequent cancers?
• How can we define rules to identify drivers in individuals?
• What are the latest emerging technologies for personalised medicine?
• What can we learn from recent trials?
Medical oncologists, interns, academics, regulators, industry R&D reps and investigators are invited to register for this important gathering to discuss clinical interpretation of molecular tests for metastatic cancers.
A joint initiative of ESMO, Cancer Research UK and UNICANCER, this conference shines a light on the latest medical developments in a constantly evolving field.
Accreditation of MAP 2017 will be announced soon. The MAP 2016 edition was accredited 12 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME).
“The MAP conference was a pleasant conference with excellent speakers. Its interactive nature allowed a very interesting share of knowledge and a refreshing update about the current investigations in personalized medicine and their interaction with the clinical practice. It was a privilege to take part in this conference and I'd absolutely recommend it to my colleagues.”
Ana Sofia Patrão, Interna de Formação Especifica Oncologia Médica Instituto Português de Oncologia - Porto
“I’m very grateful for the great opportunity I had to attend this extraordinary conference. The MAP meeting gave me the chance to understand from different perspectives the concept of translation of research findings from “the biomarker” to “the clinic” with the ultimate goal of delivering more personalized treatment strategies to our patients. The meeting has been a unique opportunity to hear the reports of the leading experts in the field of translational research in oncology. I’ve really appreciated the presence of both educational lectures and presentation of original unpublished findings. Attending the conference has been very important for my education and above all in giving me crucial insights for the development of my PhD project. ”
Dr. Matteo Lambertini, Institut Jules Bordet in Brussels (Belgium)
Dr Crispin Hiley, The Francis Crick Institute
“The MAP 2015 conference in Paris was a great experience. The science was of very high quality and there was a wide breadth of research presented, by some of the worldâ€™s most excellent scientists, in various cancer types and using different technologies and approaches. One of the best parts of the MAP conference was that there was plenty of opportunity for networking and it was easy to approach the senior PIs and speakers to discuss shared research interests.”
Dr Nicolai Birkbak, The Francis Crick Institute